The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity

The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity

Antigen heterogeneity that results in tumor antigenic escape is one of the major obstacles to successful chimeric antigen receptor (CAR) T cell therapies in solid tumors including glioblastoma multiforme (GBM). To address this issue and improve the efficacy of CAR T cell therapy for GBM, we develope...

Full description

Bibliographic Details
Main Authors: Edward Z. Song, Xin Wang, Benjamin I. Philipson, Qian Zhang, Radhika Thokala, Logan Zhang, Charles-Antoine Assenmacher, Zev A. Binder, Guo-li Ming, Donald M. O’Rourke, Hongjun Song, Michael C. Milone
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Molecular Therapy: Oncolytics
Subjects:
IAP antagonist
birinapant
CAR T cell
glioblastoma
antigen heterogeneity
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770522001395

Internet

http://www.sciencedirect.com/science/article/pii/S2372770522001395

Similar Items